PELP1/SRC-3-dependent regulation of metabolic PFKFB kinases drives therapy resistant ER+ breast cancer.

Truong, Thu H, Benner, Elizabeth A, Hagen, Kyla M, Temiz, Nuri A, Kerkvliet, Carlos Perez, Wang, Ying, Cortes-Sanchez, Emilio, Yang, Chieh-Hsiang, Trousdell, Marygrace C, Pengo, Thomas, Guillen, Katrin P, Welm, Bryan E, Dos Santos, Camila O, Telang, Sucheta, Lange, Carol A, Ostrander, Julie H (June 2021) PELP1/SRC-3-dependent regulation of metabolic PFKFB kinases drives therapy resistant ER+ breast cancer. Oncogene. ISSN 0950-9232

DOI: 10.1038/s41388-021-01871-w


Recurrence of metastatic breast cancer stemming from acquired endocrine and chemotherapy resistance remains a health burden for women with luminal (ER+) breast cancer. Disseminated ER+ tumor cells can remain viable but quiescent for years to decades. Contributing factors to metastatic spread include the maintenance and expansion of breast cancer stem cells (CSCs). Breast CSCs frequently exist as a minority population in therapy resistant tumors. In this study, we show that cytoplasmic complexes composed of steroid receptor (SR) co-activators, PELP1 and SRC-3, modulate breast CSC expansion through upregulation of the HIF-activated metabolic target genes PFKFB3 and PFKFB4. Seahorse metabolic assays demonstrated that cytoplasmic PELP1 influences cellular metabolism by increasing both glycolysis and mitochondrial respiration. PELP1 interacts with PFKFB3 and PFKFB4 proteins, and inhibition of PFKFB3 and PFKFB4 kinase activity blocks PELP1-induced tumorspheres and protein-protein interactions with SRC-3. PFKFB4 knockdown inhibited in vivo emergence of circulating tumor cell (CTC) populations in mammary intraductal (MIND) models. Application of PFKFB inhibitors in combination with ER targeted therapies blocked tumorsphere formation in multiple models of advanced breast cancer including tamoxifen (TamR) and paclitaxel (TaxR) resistant models, murine tumor cells, and ER+ patient-derived organoids (PDxO). Together, our data suggest that PELP1, SRC-3, and PFKFBs cooperate to drive ER+ tumor cell populations that include CSCs and CTCs. Identifying non-ER pharmacological targets offers a useful approach to blocking metastatic escape from standard of care ER/estrogen (E2)-targeted strategies to overcome endocrine and chemotherapy resistance.

Item Type: Paper
Subjects: organs, tissues, organelles, cell types and functions > organs types and functions > breast
diseases & disorders > cancer > cancer types > breast cancer
Investigative techniques and equipment > cell culture > cancer organoids
bioinformatics > genomics and proteomics > genetics & nucleic acid processing > protein structure, function, modification > protein types > enzymes > kinase
organism description > model organism
CSHL Authors:
Communities: CSHL labs > Dos Santos lab
SWORD Depositor: CSHL Elements
Depositing User: CSHL Elements
Date: 8 June 2021
Date Deposited: 16 Jun 2021 19:17
Last Modified: 12 Jul 2021 17:16
PMCID: PMC8238912
Related URLs:

Actions (login required)

Administrator's edit/view item Administrator's edit/view item
CSHL HomeAbout CSHLResearchEducationNews & FeaturesCampus & Public EventsCareersGiving